Who Paid My Doc
Myron Slobogean
Orthopaedic Trauma Baltimore, MD Medical Doctor
NPI 1871872986 CMS profile 1071386
22 S Greene St, Division Of Orthopaedic Traumatology, Baltimore, MD 21201
General payments
$303,854
Research payments
$1,625
Ownership & investment interest
$0
Through program year 2025, Myron Slobogean of Baltimore, MD is reported in the CMS Open Payments database as having received $303,854 across 371 general payments and $1,625 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $48,010 | 67 | |
| 2024 | General | $46,769 | 40 | |
| 2023 | General | $43,160 | 75 | |
| 2022 | General | $26,416 | 49 | |
| 2021 | General | $50,569 | 67 | |
| 2020 | General | $17,002 | 11 | |
| 2019 | General | $71,928 | 62 | |
| 2019 | Research | $1,625 | 2 |
Beside peers
- Myron Slobogean
- Orthopaedic Trauma median
- Middle half of Orthopaedic Trauma
- National median
In program year 2025, general payments to Myron Slobogean were reported at $48,010. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.
Show as a table
| Year | Myron Slobogean | Orthopaedic Trauma median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $71,928 | $1,475 | $264–$6,401 | $163 |
| 2020 | $17,002 | $596 | $120–$4,020 | $114 |
| 2021 | $50,569 | $919 | $171–$4,697 | $132 |
| 2022 | $26,416 | $1,547 | $272–$7,240 | $149 |
| 2023 | $43,160 | $1,330 | $247–$5,875 | $160 |
| 2024 | $46,769 | $1,288 | $277–$6,797 | $164 |
| 2025 | $48,010 | $1,227 | $259–$7,433 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 43 billing codesPaid by Medicare
$44,575
Medicare patients
65
Services billed
143
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 68% | |
| Depression | 52% | |
| Ischemic heart disease | 48% | |
| Diabetes | 40% | |
| Atrial fibrillation | 38% | |
| COPD | 31% | |
| Chronic kidney disease | 28% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
373 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Trauma in Maryland
Related records
Orthopaedic Trauma in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Trauma
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.